# Ofatumumab demonstrates activity against rituximab‐sensitive and ‐resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B‐cell lymphoma

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/ofatumumab-demonstrates-activity-against-rituximab-sensitive-and-resistant-cell/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Matthew J. Barth,Francisco J. Hernandez‐Ilizaliturri,Cory Mavis,Ping‐Chiao Tsai,John F. Gibbs,George Deeb,Myron S. Czuczman |
| Citations | 72 |
| DOI | 10.1111/j.1365-2141.2011.08966.x |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W1721657566 |
| PMID | 22150234 |
| Type | article |
| Year | 2011 |

## Paper authors

- [Ping‐Chiao Tsai](https://scholariq.org/researchers/ping-chiao-tsai/)

## Paper primary topic

- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)

## Paper topics

- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.